Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2820151 in Advanced or Recurrent Solid Tumors
NCT02630251Phase 1Terminated
- Sponsor
- GSK
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK2820151 in solid tumor, sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Dose Delays and Reduction and 7 more. Started Apr 2016; status: terminated.
02
Drugs
GSK2820151
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02630251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630251.